SYSMEX CORP/ADR (OTCMKTS:SSMXY) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research report issued to clients and investors on Wednesday.

According to Zacks, “Sysmex Corporation is engaged in the development, manufacture, import, export and sale of clinical laboratory instruments, reagents and software used in -vitro diagnostics. It also provides clinical laboratory testing of blood, urine and other specimens. The company’s product includes instruments and reagents diagnostics for hemostasis, immunochemistry, clinical chemistry, urinalysis and point-of-care testing. Its operating segment consists of Japan, Americas, EMEA, China and Asia Pacific. Sysmex Corporation is headquartered in Kobe, Japan. “

Shares of SSMXY stock opened at $31.06 on Wednesday. SYSMEX CORP/ADR has a fifty-two week low of $22.01 and a fifty-two week high of $50.46. The firm has a market capitalization of $12.94 billion, a PE ratio of 36.54, a PEG ratio of 4.12 and a beta of 1.00.

SYSMEX CORP/ADR Company Profile

Sysmex Corporation, together with its subsidiaries, engages in the development, manufacture, sale, and export/import of diagnostic instruments, reagents, and related software for the use in hematology, urinalysis, immunochemistry, clinical chemistry, and hemostasis. It offers three-part and five-part white blood cell differentiation instruments for use in hematology; systems for high-volume testing in labs; and hematology analyzers for animals.

Featured Story: Derivative

Get a free copy of the Zacks research report on SYSMEX CORP/ADR (SSMXY)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for SYSMEX CORP/ADR Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SYSMEX CORP/ADR and related companies with MarketBeat.com's FREE daily email newsletter.